CorEvitas announces launch of new patient registry in alopecia areata

CorEvitas, a healthcare technology company, has announced the launch of its ninth clinical registry, which will focus on patients with the autoimmune disorder alopecia areata.

The CorEvitas® Alopecia Areata Safety and Effectiveness Registry will be the first registry of its kind for this condition and will be used to collect and analyze data from patients in order to improve the understanding of alopecia areata, track the effectiveness of existing treatments and help with the development of new treatments.

Alopecia areata is an autoimmune disorder that causes hair loss on the scalp and other parts of the body, affecting almost 2 out of every 1000 individuals in the US. With several new treatments available or becoming available, understanding how these treatment work in the real world is key.

Commenting on the launch of the registry, Dr Peter Wahl, CorEvitas Vice President, Scientific Affairs & RWE, noted: “Our Alopecia Areata registry is CorEvitas’ ninth registry launch and leverages our proven model of site engagement and robust data collection. It is the first registry of its kind in alopecia areata, allowing researchers to comprehensively study JAK inhibitors and their safety and comparative effectiveness, longitudinally, in a real-world setting.”

The registry will collate various granular and longitudinal patient information data, providing researchers with insights into disease-specific severity, outcome measures, and clinician- and patient-reported outcomes (PROs) assessing symptom impact and quality of life.

With recruitment of the first patient in the Alopecia Areata Registry having already take place, Dr Brett King, Associate Professor of Dermatology, Yale School of Medicine, US and a scientific advisor on the registry explained, “This ground-breaking registry gives investigators a common protocol to collect regulatory-grade data on pivotal Phase III trial endpoints in real-world settings of care, including patient-centered outcomes, to advance our understanding of these novel and effective therapies for individuals afflicted by this disease.”